Table 1.

Preferential TCRβ CDR3 clonotypes in blister cells from patients with CBZ-SJS/TEN

Case no.	Culprit drug	Symptom		CDR3 clonotypes	TRBV	TRBJ	Frequency (%)	Specific CDR3 reads/total reads	Frequency (%) in PBMC of healthy donorsa
Case 1	CBZ	SJS/TEN	1	ASSLSDTIY	12–4	1–3	24.45	182480/746406	0
			2	ASSLGGAPY	12–4	2–7	8.41	62776/746406	0
			3	ASSYNPGTGTEEYEQY	6–1	2–7	6.50	48516/746406	0
			4	ASTHTGELF	12–4	2–2	4.60	34325/746406	0
			5	ASSLAGELF	12–4	2–2	3.73	27829/746406	<0.001
			6	ASSPRLAGSTDTQY	27	2–3	2.11	15748/746406	<0.001
Case 2	CBZ	SJS	1	ASSLAGELF	12–4	2–2	19.39	153620/792164	<0.001
			2	ASSLSGYEQY	27	2–7	4.01	31781/792164	0.0026
			3	ASSSAGEVF	12–4	2–1	2.27	17990/792164	0
Case 3	CBZ	SJS	1	ASSLAGELF	12–4	2–2	6.64	5411/81449	<0.001
			2	ATSGPNQETQY	24–1	2–5	2.08	1697/81449	0
Case 4	CBZ	TEN	1	ASSLAGELF	12–4	2–2	42.85	31148/72692	<0.001
			2	ASSYRDGYEQY	6–5	2–7	2.73	1986/72692	<0.001
			3	ASSRRAVVGSYNEQF	7–2	2–1	2.62	1905/72692	0
			4	ATHGTGYLEQY	25–1	2–7	2.15	1565/72692	0
Case 5	CBZ	SJS/TEN	1	ASSLAGELF	12–4	2–2	17.41	143248/822649	<0.001
			2	ASSSRLAGGTDTQY	27	2–3	12.11	99586/822649	0.0025
Case 6	CBZ	SJS/TEN	1	ASSPSDRSSYEQY	18	2–7	4.69	57694/1229012	0
			2	ASSSLTSSWVEQF	28	2–1	3.81	46784/1229012	0
			3	ASTSGPNEQF	12–4	2–1	2.99	36759/1229012	<0.001
			4	ASSYSSTDTQY	6–5	2–3	2.80	34429/1229012	0.0029
			5	ASSQYRYNEQF	14	2–1	2.60	32006/1229012	0
			6	ASSFAGELF	12–4	2–2	2.22	27338/1229012	<0.001
			7	ASSLAGELF	12–4	2–2	1.08	13273/1229012	<0.001
Case 7	CBZ	TEN	1	ASSWDPTIY	12–3	1–3	10.21	81449/798017	0
			2	ASSLAGELF	12–4	2–2	4.00	31881/798017	<0.001
			3	ASIDGSSLNEQF	27	2–1	3.57	28498/798017	0
			4	ASSLSGYEQY	27	2–7	2.90	23122/798017	0.0026
			5	ASSYSDTIY	6–6	1–3	2.50	19948/798017	0

CDR3 third complementarity-determining region, PBMC peripheral blood mononuclear cell, SJS Stevens–Johnson syndrome, TEN toxic epidermal necrolysis, TRBJ T-cell receptor β joining, TRBV T-cell receptor β variable

^aThe mean frequencies of the corresponding CDR3 clonotypes in PBMC of healthy donors (n = 44)